First Half 2026 Recap: Hepatology

The first half of 2026 marked a transformative period in hepatology, with major regulatory milestones, pivotal late-stage clinical trial results, and continued innovation across viral hepatitis, metabolic liver disease, and rare liver disorders. The US Food and Drug Administration (FDA) approved the first therapy for chronic hepatitis delta virus (HDV) infection and the first treatment specifically indicated for cholestatic pruritus in primary biliary cholangitis (PBC), while multiple investigational therapies advanced toward approval.